Is dermal measles-mumps-rubella-vaccine administration better thanregular injection?
Phase 1
- Conditions
- Measles, mumps, and rubellaTherapeutic area: Diseases [C] - Virus Diseases [C02]MedDRA version: 20.0Level: PTClassification code: 10027011Term: Measles Class: 100000004862Therapeutic area: Phenomena and Processes [G] - Immune System Phenomena [G13]
- Registration Number
- CTIS2023-503845-79-01
- Lead Sponsor
- Rigshospitalet
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Recruiting
- Sex
- All
- Target Recruitment
- 40
Inclusion Criteria
Age 18 to 34 years. MMR-naive. Healthy. Safe contraception for female participants.
Exclusion Criteria
Age < 18 or = 35 years. MMR-vaccinated, or MMR wild type infected. Severe, chronic disease with potential implications for the immune response, or with anemia, or thrombocytopenia. Allergy towards any vaccine component (egg, neomycin). Fructose intolerance. Blood, or plasma, or human immune serum globulin transfusion within 3 months. Pregnancy or breastfeeding.
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method